Last reviewed · How we verify

Sodium Aescinate — Competitive Intelligence Brief

Sodium Aescinate (Sodium Aescinate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vascular protective agent; phlebotropic agent. Area: Neurology; Vascular disorders.

marketed Vascular protective agent; phlebotropic agent Neurology; Vascular disorders Small molecule Live · refreshed every 30 min

Target snapshot

Sodium Aescinate (Sodium Aescinate) — Beijing Tiantan Hospital. Sodium aescinate reduces vascular permeability and edema by stabilizing capillary endothelial cells and inhibiting inflammatory mediator release.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sodium Aescinate TARGET Sodium Aescinate Beijing Tiantan Hospital marketed Vascular protective agent; phlebotropic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vascular protective agent; phlebotropic agent class)

  1. Beijing Tiantan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sodium Aescinate — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-aescinate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: